Novo Nordisk A/S logged a -0.5% change during today's evening session, and is now trading at a price of $96.21 per share. The S&P 500 index moved 0.0%. NVO's trading volume is 3,535,659 compared to the stock's average volume of 4,662,626.
Novo Nordisk A/S trades 14.4% away from its average analyst target price of $84.1 per share. The 4 analysts following the stock have set target prices ranging from $17.33 to $125.19, and on average have given Novo Nordisk A/S a rating of buy.
If you are considering an investment in NVO, you'll want to know the following:
-
Novo Nordisk A/S has moved 45.5% over the last year, and the S&P 500 logged a change of 15.0%
-
Based on its trailing earnings per share of 2.42, Novo Nordisk A/S has a trailing 12 month Price to Earnings (P/E) ratio of 39.8 while the S&P 500 average is 15.97
-
NVO has a forward P/E ratio of 30.2 based on its forward 12 month price to earnings (EPS) of $3.19 per share
-
The company has a price to earnings growth (PEG) ratio of 90.79 — a number near or below 1 signifying that Novo Nordisk A/S is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 4.63 compared to its sector average of 4.08
-
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide.
-
Based in Bagsvaerd, the company has 61,412 full time employees and a market cap of $429.09 Billion. Novo Nordisk A/S currently returns an annual dividend yield of 7.3%.